Pharma Focus Asia

Translational Medicine Guide Transforms Drug Development Processes: The Recent Merck Experience

Authors: Hugues Dolgos, Mark Trusheim, Dietmar Gross, Joern-Peter Halle, Janet Ogden, Bruno Osterwalder, Ewen Sedman5, Luciano Rossetti

Abstract:

Merck is implementing a question-based Translational Medicine Guide (TxM Guide) beginning as early as lead optimization into its stage-gate drug development process. Initial experiences with the TxM Guide, which is embedded into an integrated development plan tailored to each development program, demonstrated opportunities to improve target understanding, dose setting (i.e., therapeutic index), and patient subpopulation selection with more robust and relevant early human-based evidence, and increased use of biomarkers and simulations. The TxM Guide is also helping improve organizational learning, costs, and governance. It has also shown the need for stronger external resources for validating biomarkers, demonstrating clinical utility, tracking natural disease history, and biobanking.

Citation: Hugues Dolgos, Mark Trusheim, Dietmar Gross, Joern-Peter Halle, Janet Ogden, Bruno Osterwalder, Ewen Sedman5, Luciano Rossetti Translational Medicine Guide Transforms Drug Development Processes: The Recent Merck Experience doi:10.1016/j.drudis.2016.01.003

Available online: 14 January 2016

Copyright: © 2016 The Authors.Published by Elsevier Ltd.This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

Acknowledgments

We thank Wilhelmina Bagchus, Beatrice Brunkhorst, Laetitia Devy-Dimanche, Johannes Gleitz, Hans Juergen Grote, Stefan Hecht, Mirek Jurzak, Thekla Kurz, Noreen Nugent, Britta Paschen, Sally Pennell, Sigrid Roesener, Catherine Scholz, Kerstin Seemann, Philippe Serrano, Henry Wang, Jonathan Willmer, DeeAnn Yabusaki, Michael Zuehlsdorf, Tammy Dellovade, Klaus Duecker, Markus Fluck, Marc Gleichmann, Beatrice Greco, Caroline Kant, Scott Lauder, Ralph Lindemann, Giorgio Massimini, Alain Munafo, Florence Porte, Oliver von Richter, Frank Zenke. Special thanks to Berndt Kirschbaum, and Anna-Lisa Jenkins for their executive sponsorship during their tenure. In addition, we thank Stefan Jaekel, Simon Geissler, and Ken Hance (case study 1); Brigitte Brockhaus, Pascal Girard and B. Meibohm (case study 2); and Hui Tian (case study 3) and to Feinstein Kean Healthcare for assistance with the figures.

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024